- Home
- ALLO vs LXRX Comparison
ALLO vs LXRX Comparison
Compare ALLO & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLO | LXRX |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 703.3M |
| IPO Year | 2018 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ALLO | LXRX |
|---|---|---|
| Price | $2.07 | $2.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 2 |
| Target Price | ★ $8.35 | $4.15 |
| AVG Volume (30 Days) | ★ 9.0M | 4.0M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.09 | ★ 77.78 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $0.99 | $0.87 |
| 52 Week High | $4.46 | $2.67 |
Technical Indicators
Market Signals| Indicator | ALLO | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 62.90 |
| Support Level | $1.85 | $1.52 |
| Resistance Level | $2.36 | $2.53 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 60.00 | 68.45 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.